Welcome!

News Feed Item

Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation



 

 

 

 

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation


Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation

Summary

GBI Research has released its pharmaceuticals report, "Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation". The Alzheimer's Disease (AD) market is characterized by a lack of products with strong disease-modifying properties and a number of high-profile product failures in late stages of development over recent years. In addition, recent or impending patent expiries for all of the four currently marketed products and a late-stage pipeline with limited-to-moderate prospects are expected to impede growth over the next few years. In the medium-term future, the market is expected to be characterized by substantial generic competition and overall decline. However, the current development pipeline shows signs of meaningful innovation, although the vast majority of these products are currently in the early stages of development. Despite one of the highest drug attrition rates across the industry, a number of innovative and potentially disease-modifying therapeutics are likely to enter the market and translate recent insights into the etiology of AD combined with an earlier therapeutic intervention into better products, which will begin to transform the AD market towards the end of the decade.


Scope

- A brief introduction to AD etiology, pathogenesis, diagnosis, and treatment regimes
- Profiling of the marketed products in the AD market, including analysis of their safety, efficacy, treatment patterns, and strengths and weaknesses
- Comprehensive review of the pipeline for AD therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule type, and molecular target.
- Additional in-depth analysis of pipeline drug clinical trials, analyzed by phase, molecule type, trial size, trial duration and program failure rate, for each molecule type and mechanism of action
- Multi-scenario forecast data for the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Japan, Germany, the UK, France, Italy and Spain
- Discussion of the drivers of and barriers to market growth
- Analysis of the licensing and co-development deals landscape

Reasons to buy

- Understand the different levels of AD therapies, from early-stage or mild AD to severe AD
- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
- Observe trends in terms of clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for AD therapeutics
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the AD therapeutics market
Table of Contents

1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Symptoms 8
2.2 Etiology 9
2.3 Pathophysiology 10
2.3.1 Amyloidosis 10
2.3.2 Tau Hyperphosphorylation 10
2.4 Comorbidities/Complications 11
2.5 Diagnosis 11
2.5.1 Physical Examination 12
2.5.2 Mini Mental State Exam 12
2.5.3 Alzheimer's Disease Assessment Scale-cognitive 14
2.5.4 Alzheimer's Disease Co-operative Study – Activities of Daily Living Inventory 15
2.5.5 Other Diagnostic Tests 15
2.5.6 Blood Tests 15
2.5.7 Imaging Tests 15
2.5.8 Lumbar Puncture 15
2.5.9 Disease Biomarkers 16
2.5.10 Biomarker Market 17
2.6 Prognosis 18
2.7 Treatment Options 18
2.7.1 Treatment Algorithm 19
2.7.2 Non-Pharmacological Treatments 19
3 Marketed Products 20
3.1 Namenda/Axura/Memary (memantine), Merz Pharma/Lundbeck/Forest Laboratories/Daiichi Sankyo 20
3.2 Aricept (donepezil), Eisai Inc. 21
3.3 Exelon (rivastigmine), Novartis AG 22
3.4 Razadyne (galantamine), Janssen Pharmaceuticals 22
3.5 Cognex (tacrine), Shiniogi Inc. 23
3.6 Unmet Need 24
4 Pipeline for Alzheimer's Disease Therapeutics 25
4.1 Overall Pipeline 25
4.2 Mechanisms of Action within the AD Pipeline 27
4.3 Clinical Trials 29
4.3.1 Clinical Trial Failure Rate 29
4.3.2 Clinical Trial Size 33
4.3.3 Clinical Trial Duration 35
4.4 Notable Pipeline Drugs 38
4.4.1 Solanezumab – Eli Lilly and Company 38
4.4.2 LMTX (Methylene Blue) – TauRX Therapeutics Ltd. 39
4.4.3 RG-1540 (gantenerumab) – Roche 39
4.4.4 AD-02 – AFFiRiS AG 40
4.4.5 MK-8931 – Merck & Co. 41
4.4.6 CAD-106 – Novartis AG 41
4.4.7 LuAE58054 – Lundbeck 42
4.4.8 Crenezumab (RG7412) – Genentech 42
4.5 Conclusion 42
5 Market Forecast to 2019 44
5.1 Geographical Markets 44
5.1.1 Key Developed Markets 44
5.1.2 US 47
5.1.3 Leading Five EU Countries (EU5) 49
5.1.4 Japan 53
5.2 Drivers and Barriers 55
5.2.1 Drivers 55
5.2.2 Barriers 56
6 Deals and Strategic Consolidations 58
6.1 Key Licensing Deals 58
6.1.1 Forest Laboratories Inc. Enters into Agreement with Adamas Pharmaceuticals Inc. 60
6.1.2 AC Immune SA Enters into an Agreement with Genentech Inc. 60
6.1.3 Cephalon Inc. Enters into Agreement with Mesoblast Limited 60
6.1.4 Acadia Pharmaceuticals Inc. Enters into Agreement with Biovail Laboratories International SRL 60
6.1.5 Astellas Pharma Inc. enters into Agreement with CoMentis Inc. 61
6.2 Key Co-development Deals 61
6.2.1 Evotec AG Enters into Agreement with F. Hoffman-La Roche Ltd. 63
6.2.2 Alectos Therapeutics Inc. Enters into Agreement with Merck & Co. Inc. 63
6.2.3 Targacept Inc. Expands Agreement with AstraZeneca PLC. 63
6.2.4 GlaxoSmithKline Enters into an Agreement with Epix Pharmaceuticals 64
7 Appendix 65
7.1 All Pipeline Drugs by Phase – Tables 65
7.2 Market forecast to 2019 - Tables 81
7.3 References 84
7.4 Abbreviations 87
7.5 Methodology 89
7.6 Secondary Research 89
7.7 Therapeutic Landscape 90
7.8 Contact Us 90
7.9 Disclaimer 90



List of Tables


Table 1: Alzheimer's Disease, Global, All Pipeline Products (Discovery) 65
Table 2: Alzheimer's Disease, Global, All Pipeline Products (Preclinical) 68
Table 3: Alzheimer's Disease, Global, All Pipeline Products (Phase I) 76
Table 4: Alzheimer's Disease, Global, All Pipeline Products (Phase II) 79
Table 5: Alzheimer's Disease, Global, All Pipeline Products (Phase III) 81
Table 6: Alzheimer's Disease, Global, Market Forecast, 2012–2019 81
Table 7: Alzheimer's Disease, US, Market Forecast, 2012–2019 81
Table 8: Alzheimer's Disease, UK, Market Forecast, 2012–2019 82
Table 9: Alzheimer's Disease, France, Market Forecast, 2012–2019 82
Table 10: Alzheimer's Disease, Germany, Market Forecast, 2012–2019 82
Table 11: Alzheimer's Disease, Italy, Market Forecast, 2012–2019 83
Table 12: Alzheimer's Disease, Spain, Market Forecast, 2012–2019 83
Table 13: Alzheimer's Disease, Japan, Market Forecast, 2012–2019 83



List of Figures



Figure 1: Mini-Mental State Exam 13
Figure 2: Alzheimer's Disease Assessment Scale Cognitive Subscale 14
Figure 3: Alzheimer's Disease, Overall Pipeline 26
Figure 4: Alzheimer's Disease, Mechanisms of Action in the Pipeline, 2006–2013 29
Figure 5: Alzheimer's Disease, Failure Rates of Clinical Trials, 2006–2013 30
Figure 6: Alzheimer's Disease, Failure Rates by Mechanism of Action, 2006–2013 31
Figure 7: Alzheimer's Disease, Reasons for Clinical Trial Failure, 2006–2013 32
Figure 8: Alzheimer's Disease, Clinical Trial Size by Phase, 2006–2013 33
Figure 9: Alzheimer's Disease, Clinical Trial Size by Molecule Type, 2006–2013 34
Figure 10: Alzheimer's Disease, Clinical Trial Duration by Phase, 2006–2013 35
Figure 11: Alzheimer's Disease, Clinical Trial Duration by Molecule Type, 2006–2013 36
Figure 12: Alzheimer's Disease, Global, 2012–2019 46
Figure 13: Alzheimer's Disease, US, 2012–2019 48
Figure 14: Alzheimer's Disease, EU5, Patient Number ('000) 2012–2019 50
Figure 15: Alzheimer's Disease, EU5, Annual Cost of Treatment ($), 2012–2019 51
Figure 16: Alzheimer's Disease, EU5, Market Size ($m), 2012–2019 52
Figure 17: Alzheimer's Disease, Japan, 2012–2019 54
Figure 18: Alzheimer's Disease, Global, Licensing Deals by Region and Year, 2012–2019 58
Figure 19: Alzheimer's Disease, Global, Licensing Deals by Phase and Molecule Type, 2012–2019 59
Figure 20: Alzheimer's Disease, Global, Co-development Deals by Region and Year, 2012–2019 61
Figure 21: Alzheimer's Disease, Global, Co-development Deals by Phase and Molecule Type, 2006–2013 62


Read the full report:
Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation
http://www.reportbuyer.com/pharma_healthcare/treatments/alzheimers_disea...

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo Silicon Valley Call for Papers is now open.
SYS-CON Events announced today that Twistlock, the leading provider of cloud container security solutions, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Twistlock is the industry's first enterprise security suite for container security. Twistlock's technology addresses risks on the host and within the application of the container, enabling enterprises to consistently enforce security policies, monitor...
This talk centers around how to automate best practices in a multi-/hybrid-cloud world based on our work with customers like GE, Discovery Communications and Fannie Mae. Today’s enterprises are reaping the benefits of cloud computing, but also discovering many risks and challenges. In the age of DevOps and the decentralization of IT, it’s easy to over-provision resources, forget that instances are running, or unintentionally expose vulnerabilities.
SYS-CON Events announced today that Ocean9will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Ocean9 provides cloud services for Backup, Disaster Recovery (DRaaS) and instant Innovation, and redefines enterprise infrastructure with its cloud native subscription offerings for mission critical SAP workloads.
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
While some vendors scramble to create and sell you a fancy solution for monitoring your spanking new Amazon Lambdas, hear how you can do it on the cheap using just built-in Java APIs yourself. By exploiting a little-known fact that Lambdas aren’t exactly single threaded, you can effectively identify hot spots in your serverless code. In his session at 20th Cloud Expo, David Martin, Principal Product Owner at CA Technologies, will give a live demonstration and code walkthrough, showing how to ov...
SYS-CON Events announced today that Enzu will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive ad...
Everywhere we turn in our industry we can find strong opinions about the direction, type and nature of cloud’s impact on computing and business. Another word that is used in every context in our industry is “hybrid.” In his session at 20th Cloud Expo, Alvaro Gonzalez, Director of Technical, Partner and Field Marketing at Peak 10, will use a combination of a few conceptual props and some research recently commissioned by Peak 10 to offer a real-world consideration of how the various categories of...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
SYS-CON Events announced today that Interoute has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Interoute is the owner operator of Europe's largest network and a global cloud services platform, which encompasses over 70,000 km of lit fiber, 15 data centers, 17 virtual data centers and 33 colocation centers, with connections to 195 additional partner data centers. Our full-service Unifie...
SYS-CON Events announced today that CollabNet, a global leader in enterprise software development, release automation and DevOps solutions, will be a Bronze Sponsor of SYS-CON's 20th International Cloud Expo®, taking place from June 6-8, 2017, at the Javits Center in New York City, NY. CollabNet offers a broad range of solutions with the mission of helping modern organizations deliver quality software at speed. The company’s latest innovation, the DevOps Lifecycle Manager (DLM), supports Value S...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus intern...
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
SYS-CON Events announced today that Linux Academy, the foremost online Linux and cloud training platform and community, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Linux Academy was founded on the belief that providing high-quality, in-depth training should be available at an affordable price. Industry leaders in quality training, provided services, and student certification passes, its goal is to c...